NewAmsterdam Pharma reports Q1 results, keeps obicetrapib regulatory and Phase 3 timelines
NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.